chartexchange

BioNTech May Be the Next Moderna. Even if it Isn’t, the Stock Is a Buy.

Barron's | Nov 13, 2026 11:17 AM EST

The firm has multiple catalysts that could generate a rally of 35% for the stock.

Read original article